In 2011, patents with atrial fibrillation, those with potentially deadly blood clots in their legs and lungs, and those undergoing knee and hip surgeries, also making them susceptible to blood clots, were told they could count on a new drug to protect them – Xarelto.
But Xarelto has a fatal side effect. Patients taking the new blood thinner can bleed to death.
By December 2014, the drug company that makes Xarelto was facing numerous lawsuits filed by relatives who lost loved ones or suffered serious bleeding events themselves. The suits claimed that Xarelto’s manufacturer “…didn’t properly test the blood thinner before putting it on the market, hid the fact the medicine had no antidote and overstated its effectiveness…,” according to Bloomberg News.
The news agency also revealed that “more than 1,000 reports of side effects were filed with the U.S. Food and Drug Administration by June 2012, including at least 65 deaths…”
Xarelto was approved by the U.S. Food Drug Administration (FDA) in 2011. It was developed to replace Warfarin, a blood thinner that doctors have been using since the 1960s to protect patients from blood clots. But Warfarin has restrictions. Patients on Warfarin must have frequent tests at doctor’s offices to check their blood levels and they must follow a special diet.
Xarelto has no restrictions. But unlike Warfarin, it has no antidote. Doctors can give Vitamin K to patients on Warfarin and stop a serious bleed. Patients on Xarelto can easily bleed to death. There are many accounts of doctors unable to save patients who arrived at emergency rooms, “walking and talking,” but died within a few hours no matter what doctors did to save their lives.
The director of clinical research for emergency medicine at the Icahn School of Medicine at Mount Sinai Hospital in New York City questions why the FDA approves drugs like Xarelto so quickly.
“…the current process for FDA drug approval often means it takes years after a drug is approved before we learn of its dangers,” David Newman told the Milwaukee Journal Sentinel.
An FDA reviewer, also interviewed by Journal Sentinel, says Xarelto’s manufacturer didn’t test the drug in the United States. Instead, medical trials for the drug were conducted around the world. That, he says, “…may have biased the results in favor of Xarelto…”
The reviewer also noted that patients taking Xarelto “…might be at greater risk of harm from stroke and/or bleeding than if they were treated with warfarin used skillfully…”
For more than 30 years, Wayne Wright LLP has been helping victims of drug companies that misrepresent the advantages of their medications and downplay their dangers. Anyone who lost a loved one, or suffered a serious hemorrhage while taking Xarelto, can have confidence that Wayne Wright’s lawyers will represent their interests with the knowledge and legal expertise that produces results.